DEEPVESSEL FFR

About Keya Medical

Keya Medical is a commercial-stage AI diagnostics company focused on revolutionizing the assessment of coronary artery disease. Its core technology, DEEPVESSEL FFR, provides a non-invasive, AI-powered physiological analysis (FFRCT) from standard coronary CT angiography (CCTA) scans, helping clinicians determine if a patient requires invasive intervention. The company has achieved significant regulatory milestones, including FDA clearance (2022), CE Mark (2018), and NMPA approval in China (2020), and is benefiting from the establishment of a new Category I CPT code (75580) in the U.S. for FFRCT analysis. Keya Medical operates globally, with its software available in the USA, EMEA, China, and Singapore, positioning it at the intersection of the rapidly growing AI healthcare and cardiovascular diagnostics markets.

About Precision Image Analysis

Precision Image Analysis (PIA) operates as an outsourced, virtual post-processing partner for advanced medical imaging, primarily in cardiac, vascular, and neuro applications. The company leverages a cloud-based platform to deliver analysis and reports on a pay-per-use model, eliminating the need for clients to invest in expensive software, hardware, and specialized in-house staff. PIA's value proposition centers on reducing operational costs by up to 50%, guaranteeing turnaround times, and seamlessly integrating into existing hospital PACS and workflows. It is a commercial-stage, revenue-generating services company targeting healthcare systems seeking to improve efficiency and standardization in 3D image analysis.

Therapeutic Areas

Other Hemodynamically significant coronary artery disease Drugs